Dec 9, 2025
ONL Therapeutics reports positive phase 1b data for xelafaslatide in geographic atrophy
Author(s): Martin David Harp Key Takeaways Xelafaslatide, a Fas inhibitor, shows promise in protecting retinal cells and slowing GA progression in dry AMD. The phase 1b study evaluated safety and…